mon-te-LOO-kast 
Therapeutic Classification: allergy, cold and cough remedies, bronchodilators
Pharmacologic Classification: leukotriene antagonists
Absorption: Rapidly absorbed (63–73%) following oral administration.
Distribution: Minimally distributed to tissues.
Protein Binding: 99%.
Metabolism/Excretion: Mostly metabolized by the liver by the CYP3A4 and CYP2C9 isoenzymes; metabolites eliminated in feces via bile; negligible renal excretion.
Half-life: 2.7–5.5 hr.
(improved symptoms of asthma)
| ROUTE | ONSET | PEAK† | DURATION |
|---|---|---|---|
| PO (swallow) | within 24 hr | 3–4 hr | 24 hr |
| PO (chew) | within 24 hr | 2–2.5 hr | 24 hr |
†Plasma concentrations.
Contraindicated in:
Use Cautiously in:
Derm: rash, STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS.
EENT: epistaxis, otitis (children), rhinorrhea, sinusitis (children).
GI: ↑ liver enzymes, abdominal pain, diarrhea (children), dyspepsia, nausea (children).
Neuro: aggression, agitation, anxiety, attention disturbance, depression, disorientation, dream abnormalities, fatigue, hallucinations, headache, insomnia, irritability, memory impairment, obsessive-compulsive symptoms, restlessness, sleep walking, stuttering, SUICIDAL BEHAVIORS/THOUGHTS, tics, tremor, weakness.
Resp: cough.
Misc: EOSINOPHILIC CONDITIONS (INCLUDING CHURG-STRAUSS SYNDROME), fever.
Drug-Drug:
Asthma
Exercise-Induced Bronchoconstriction
Allergic Rhinitis
(Generic available)
NDC Code*
